Decision: Favourable

Decisions Table

Study Title:

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96 / ENGOT-ov65)

  • NREC Code:

    21-NREC-CT-134

  • Decision:

    Favourable

  • Meeting Date:

    17/11/2021

  • Study Type:

    CT application

  • Principal Investigator:

    Dr Dearbhaile Collins

  • PI Institution:

    Cork University Hospital

  • Sponsor:

    MSD

Scroll to Top